-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases

Reuters·03/27/2026 16:25:56

Please log in to view news